It’s turning out to be one
of the biggest epidemic waves in American history, with estimated costs
nationally jumping approximately 40% in just the past 5 years, to roughly $1/4
trillion annually. The epidemic is diabetes, and the size and scope of the problem,
including the disastrous drain on the country’s economy, is just now beginning
to be fully appreciated. Less obvious and dramatic than high-profile diseases
such as cancer, the hidden power behind the diabetes epidemic is that it
affects so many people. It is now estimated that over 25 million Americans have
the disease, though many are not aware of it, with nearly 80 million Americans
in a state of prediabetes. Diabetes complications include heart disease,
stroke, kidney damage, and retinopathy.
Driven, it is believed, by a
generation of negative dietary and life style habits, diabetes is now becoming
one of America’s primary healthcare targets. Unfortunately, such habits, and
the industries that support them, are slow to change, and today there is a
desperate need for medical technologies that can help stem the epidemic tide
more quickly.
Boston Therapeutics believes
it has developed the most effective single solution with PAZ320, the company’s
non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and
its complications. The drug is currently undergoing clinical trials after
getting promising results in initial studies. PAZ320 would be a miracle to
millions of diabetic and prediabetic patients, or anyone seeking to better
manage blood glucose levels, by inhibiting the enzymes that release glucose
from complex carbohydrates in foods during digestion. As a result, the drug now
has a near-term opportunity in what is already a $35 billion diabetes drug
market.
PAZ320 is not Boston Therapeutic’s
only product. They are also in pre-clinical stage development of IPOXYN, an
injectable universal oxygen carrier for the prevention of necrosis and
treatment of ischemic conditions which may lead to necrosis, and OxyFex, a
veterinary facsimile to Ipoxyn.
For additional information,
visit www.BostonTI.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
